Revvity (RVTY) fundamentals: P/E, valuation, undervalued?
Revvity · Health Care · ref. ETF XLV · price $155.08
In short — Revvity trades at 74.6× earnings (P/E), 26.3× forward, with a net margin of 8.2 % and revenue growth of +1 %. Read: Very high P/E (P/E 75 (well above average)).
Is Revvity stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$155.08+70.2% over range
Oct 14, 25low $82.26 · high $157.36Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
56% recommend buying · 9 analysts
Valuation : Very high P/E — P/E 75 (well above average)
Valuation
74.6
P/E (price/earnings)
26.3
Forward P/E
62.13
PEG
2.4
Price/book (P/B)
$17.3B
Market cap
2.08
EPS
Profitability & growth
8.2 %
Net margin
+1 %
Revenue growth
+1 %
Earnings growth
$3.3B
Total debt
Revvity income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $4.6B | $579M | 12.6 % |
| 2023 | $2.8B | $693M | 25.2 % |
| 2024 | $2.8B | $270M | 9.8 % |
| 2025 | $2.9B | $241M | 8.4 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Revvity's P/E and is the stock undervalued? What's a good P/E?
Revvity's P/E is 74.6 (forward 26.3). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Very high P/E".
Is Revvity profitable?
Revvity has a net margin of 8.2 % (EPS 2.08). The company is profitable.
Is RVTY stock expensive?
Our read: "Very high P/E" — P/E 75 (well above average). Cross-check with growth and sector.
💬 A question about Revvity? The JPI assistant answers using our backtest data.